Table I.

Characteristics of COVID-19 patients and sample cohorts in epitope mapping

Patient ID	Age (years)	Sex	Disease severity	Duration of illness (days)	Serum samples
					Sample ID	Sampling days after disease onset	SARS-CoV-2
							S binding IgG titer (log10)	Neutralization (NT50)
1	39	F	Moderate	14	1-1	16	4.10	237.32
					1-2	118	3.68	60.71
					1-3	186	3.66	20.00
2	54	F	Moderate	15	2-1	18	4.13	178.04
					2-2	118	4.33	232.92
					2-3	198	4.32	126.74
3	26	M	Moderate	17	3-1	27	4.46	468.97
					3-2	126	4.09	165.02
					3-3	205	3.89	77.08
4	52	F	Moderate	16	4-1	17	4.29	285.41
					4-2	114	4.13	157.25
					4-3	183	3.94	172.55
5	56	F	Moderate	14	5-1	23	4.22	186.14
					5-2	119	3.78	40.95
					5-3	187	3.68	50.29
6	50	F	Moderate	14	6-1	18	3.93	445.35
					6-2	114	4.28	324.84
					6-3	182	4.55	127.41
7	54	M	Moderate	20	7-1	13	4.67	216.59
					7-2	109	4.72	233.08
					7-3	197	4.33	100.53
8	44	F	Moderate	9	8-1	26	4.64	443.69
					8-2	124	3.81	233.08
					8-3	211	3.64	100.53
9	52	F	Moderate	19	9-1	20	4.63	222.13
					9-2	116	4.99	664.89
					9-3	204	4.70	384.45
10	41	M	Moderate	13	10-1	41	4.31	169.26
					10-2	143	4.24	106.33
					10-3	219	4.13	37.05
11	66	F	Moderate	10	11-1	23	4.61	441.91
					11-2	125	4.14	106.40
					11-3	202	3.83	84.84
12	30	M	Moderate	28	12-1	23	3.75	437.74
					12-2	44	3.91	341.81
					12-3	121	3.67	103.08
13	64	M	Moderate	19	13-1	124	4.08	64.01
					13-2	193	4.12	20.00
14	66	M	Mild	19	14-1	123	4.07	136.81
					14-2	192	3.98	87.88
15	38	F	Severe	22	15-1	20	4.45	243.80
					15-2	192	4.25	174.08
16	30	M	Moderate	45	16-1	15	3.98	60.65
					16-2	44	3.85	62.50
					16-3	146	3.85	69.30
17	20	M	Moderate	22	17-1	18	3.37	68.51
					17-2	107	3.30	20.00
18	17	M	Mild	30	18-1	52	3.82	167.14
					18-2	114	3.70	53.26
19	45	F	Asymptomatic	—	19-1	111	3.78	<20
					19-2	187	3.66	<20